Insulin icodec (Awiqli)

Reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial governments, with the exception of Quebec. This review assesses insulin icodec (Awiqli), solution for once-weekly subcutaneous injection. Indication: The once-weekly treatment of adults with diabetes mellitus to improve glycemic control.